Template:PDB Gallery/3683

• 1cqp: CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION

  1cqp: CRYSTAL STRUCTURE ANALYSIS OF THE COMPLEX LFA-1 (CD11A) I-DOMAIN / LOVASTATIN AT 2.6 A RESOLUTION

• 1dgq: NMR SOLUTION STRUCTURE OF THE INSERTED DOMAIN OF HUMAN LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1

  1dgq: NMR SOLUTION STRUCTURE OF THE INSERTED DOMAIN OF HUMAN LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1

• 1lfa: CD11A I-DOMAIN WITH BOUND MN++

  1lfa: CD11A I-DOMAIN WITH BOUND MN++

• 1mjn: Crystal Structure of the intermediate affinity aL I domain mutant

  1mjn: Crystal Structure of the intermediate affinity aL I domain mutant

• 1mq8: Crystal structure of alphaL I domain in complex with ICAM-1

  1mq8: Crystal structure of alphaL I domain in complex with ICAM-1

• 1mq9: Crystal structure of high affinity alphaL I domain with ligand mimetic crystal contact

  1mq9: Crystal structure of high affinity alphaL I domain with ligand mimetic crystal contact

• 1mqa: Crystal structure of high affinity alphaL I domain in the absence of ligand or metal

  1mqa: Crystal structure of high affinity alphaL I domain in the absence of ligand or metal

• 1rd4: An allosteric inhibitor of LFA-1 bound to its I-domain

  1rd4: An allosteric inhibitor of LFA-1 bound to its I-domain

• 1t0p: Structural Basis of ICAM recognition by integrin alpahLbeta2 revealed in the complex structure of binding domains of ICAM-3 and alphaLbeta2 at 1.65 A

  1t0p: Structural Basis of ICAM recognition by integrin alpahLbeta2 revealed in the complex structure of binding domains of ICAM-3 and alphaLbeta2 at 1.65 A

• 1xdd: X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution

  1xdd: X-ray structure of LFA-1 I-domain in complex with LFA703 at 2.2A resolution

• 1xdg: X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution

  1xdg: X-ray structure of LFA-1 I-domain in complex with LFA878 at 2.1A resolution

• 1xuo: X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution

  1xuo: X-ray structure of LFA-1 I-domain bound to a 1,4-diazepane-2,5-dione inhibitor at 1.8A resolution

• 1zon: CD11A I-DOMAIN WITHOUT BOUND CATION

  1zon: CD11A I-DOMAIN WITHOUT BOUND CATION

• 1zoo: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION

  1zoo: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION

• 1zop: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION

  1zop: CD11A I-DOMAIN WITH BOUND MAGNESIUM ION

• 2ica: CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid

  2ica: CD11a (LFA1) I-domain complexed with BMS-587101 aka 5-[(5S, 9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro [4.4]non-7-yl]methyl]-3-thiophenecarboxylicacid

• 2o7n: CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile

  2o7n: CD11A (LFA1) I-domain complexed with 7A-[(4-cyanophenyl)methyl]-6-(3,5-dichlorophenyl)-5-oxo-2,3,5,7A-tetrahydro-1H-pyrrolo[1,2-A]pyrrole-7-carbonitrile